Balance Sheet Detail - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands |
Jun. 30, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Accrued Liabilities, Current [Abstract] | ||
| Product revenue allowances | $ 2,170 | $ 377 |
| Accrued clinical trial research and development expenses | 20,086 | 23,276 |
| Accrued other research and development expenses | 14,655 | 12,041 |
| Accrued compensation and benefits | 14,344 | 22,372 |
| Other accrued expenses | 3,498 | 3,392 |
| Income taxes payable | 59 | 239 |
| Total accrued expenses and other current liabilities | $ 54,812 | $ 61,697 |
| X | ||||||||||
- Definition Accrued clinical trial research and development expenses current. No definition available.
|
| X | ||||||||||
- Definition Accrued other research and development expenses. No definition available.
|
| X | ||||||||||
- Definition Product revenue allowances current. No definition available.
|
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|